Merck Scores Another Target -- Smaller Scale M&A / R&D, In The Eye Care Space -- Min: $1.3 Billion; Max: $3 Billion For EyeBio.

Again, this is at the moment immaterial to vast Merck.

But it is smart diversifying / back-filling. . . for the 2030s -- at a very fair price, as well. Very smart. Here's the bit:

. . .Merck & Co is nearing a $1.3 billion cash deal to buy ophthalmology biotechnology company EyeBio in an agreement that could see an additional $1.7 billion in milestone payments, the Wall Street Journal reported on Tuesday.

The deal could be announced as early as Wednesday, the report said, citing people familiar with the matter.

Merck did not immediately respond to Reuters' request for a comment, while EyeBio declined to comment. . . .

Now you know -- off to the steel and glass canyons, under a bright and sunny sky. . . grin.

नमस्ते